Ablynx reports TTP data for caplacizumab

Ablynx N.V. (Euronext:ABLX) said a single bolus of caplacizumab ( anti-vWF Nanobody) followed by once-daily caplacizumab as adjunctive treatment to standard of care (SOC) plasma exchanges met the primary endpoint of reducing time to confirmed platelet normalization vs. placebo plus SOC in the Phase II TITAN trial to treat thrombotic thrombocytopenic purpura ( TTP) (p=0.013). The single-blind, international trial enrolled 75 patients with acquired TTP. Ablynx previously reported interim data from five patients. ...